Efficacy and Safety of Topiramate for Prophylactic Treatment of Children Suffering from Moderate Migraine: A Randomized Controlled Trial

Authors

  • Banita Mistry Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Most Shameem Ara Begum Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Nazmul Haq Assistant Professor, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Most Samsun Nahar Sumi Junior Consultant, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh
  • Palash Kanti Mistry Registar, National Institute of Ophthalmology & Hospital, Dhaka, Bangladesh
  • Narayan Saha Professor & Head, Department of Paediatric Neurology, National Institute of Neurosciences & Hospital, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/jninb.v8i1.59927

Keywords:

Moderate migraine; topiramate; efficacy

Abstract

Background: Paediatric migraine is the most common cause of recurrent headache in children.

Objective: The purpose of the study was to assess the efficacy and tolerability of topiramate for prophylactic treatment of children suffering from moderate migraine.

Methodology: This randomized controlled trial was done in the outpatient department of Paediatric Neurology at National Institute of Neurosciences, Dhaka, Bangladesh from January to July, 2018. Children of 5 to 15years with migraine of moderate intensity were randomized into study group (TPM treatment group) and control group (FNZ treatment group). The efficacy and safety of TPM was assessed after 4 months of treatment.

Results: There was significant reduction of frequency of headache /month in both groups after treatment (within group, 4.65 ± 1.59 vs1.70 ± 0.73, p <0.001 for FNZ, 5.20 ± 1.73 vs 1.75 ± 0.71, p <0.001 for TPM). The efficacy of two drugs was not different in moderate intensity of migraine p being 0.304 and 0.828.

Conclusion: Topiramate is effective as well as safe in prophylaxis of children suffering from moderate migraine.

Journal of National Institute of Neurosciences Bangladesh, January 2022; 8(1):19-22

Downloads

Download data is not yet available.
Abstract
1
PDF
0

Downloads

Published

2022-05-27

How to Cite

Mistry, B. ., Ara Begum, M. S., Haq, N. ., Nahar Sumi, M. S., Mistry, P. K. ., & Saha, N. . (2022). Efficacy and Safety of Topiramate for Prophylactic Treatment of Children Suffering from Moderate Migraine: A Randomized Controlled Trial. Journal of National Institute of Neurosciences Bangladesh, 8(1), 19–22. https://doi.org/10.3329/jninb.v8i1.59927

Issue

Section

Original Research Articles